Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For KorsuvaSeeking Alpha • 07/14/23
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusPRNewsWire • 05/18/23
Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023MarijuanaStocks • 05/01/23
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023GlobeNewsWire • 05/01/23
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/10/23
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)Benzinga • 03/14/23
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance ReportGlobeNewsWire • 03/14/23
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/06/23
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/06/23
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 02/27/23
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023GlobeNewsWire • 02/21/23
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of MedicineGlobeNewsWire • 02/08/23
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23